Business EconomyPosted at: Oct 14 2025 12:14AM


Bristol Myers Squibb launches Kopozgo in India for treatment of symptomatic Obstructive Hypertrophic Cardiomyopathy

Hyderabad, Oct 13 (UNI) Bristol Myers Squibb (BMS) today announced the launch of Kopozgo® (Mavacamten) in India -- the first and only oral, selective cardiac myosin inhibitor approved in the country for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II–III obstructive hypertrophic cardiomyopathy (OHCM).
Symptomatic obstructive HCM is an often-inherited heart disease that can be a chronic, debilitating and progressive condition where patients may experience symptoms of shortness of breath, dizziness and fatigue as well as serious, life-altering complications, including heart failure, arrhythmias, stroke and in rare cases (~1%) sudden cardiac death.
It affects about 1 in 500 people worldwide, and it is estimated that as many as 2.8 million people in India may be living with the condition; however, 80-90 % patients remain undiagnosed.
Existing medical treatments in India, such as beta blockers, calcium channel blockers, and disopyramide, reduce symptoms but do not address the underlying cause.
Kopozgo is the first in-class disease-specific treatment targeting the core pathophysiological mechanism of obstructive HCM, leading to improvement in functional capacity of heart and symptoms.
Mavacamten was approved by the Central Drugs Standard Control Organisation (CDSCO) with an import license issued on March 6, 2025.
Kopozgo is now available to patients in India.
The approval of Kopozgo in India is based on positive efficacy and safety results from two Phase III clinical trials, EXPLORER-HCM and VALOR-HCM.
Sanjay Sharma, General Manager and Managing Director, BMS India, mentioned, “With the launch of Kopozgo in India, patients with oHCM now have a promising first-in-class treatment option. This breakthrough brings hope to individuals and families facing this condition, giving clinicians a novel therapy to address the unmet need in treatment. Bristol Myers Squibb is committed to advancing cardiovascular care for patients in India.”
Globally, mavacamten has been widely recognized, with its first approval granted by the U.S. Food and Drug Administration (FDA) on April 28, 2022, followed by approval from the European union on June 26, 2023.
Since then, the medicine has continued to expand its reach, receiving marketing authorization in more than 50 countries, underscoring its global significance as a breakthrough therapy for symptomatic obstructive hypertrophic cardiomyopathy. UNI KNR SS
Please log in to get detailed story.
Tags: #Bristol Myers Squibb launches Kopozgo in India for treatment of symptomatic Obstructive Hypertrophic Cardiomyopathy
More News

Indo-US Business Summit showcases UP as India’s growth engine

15 Nov 2025 | 2:29 AM

Lucknow, Nov 14 (UNI) The Indo-US Business Summit 2025, held in collaboration with Invest UP and the Indo-American Chamber of Commerce in Lucknow, brought together leading voices from government and industry to spotlight Uttar Pradesh’s accelerating economic momentum and its expanding role in driving India’s growth story.

see more..

TVS InvIT inaugurates Rs 250 cr industrial park

15 Nov 2025 | 1:54 AM

Visakhapatnam (Andhra Pradesh), Nov 14 ((UNI): TVS Infrastructure Trust inaugurated the expanded phase of its flagship Tarkeshwar Industrial & Logistics Park here.

see more..

Capillary Technologies IPO opens at ₹549–₹577

15 Nov 2025 | 1:11 AM

Bengaluru, Nov 14 (UNI) Capillary Technologies India Limited opened its Initial Public Offer (IPO) on Friday, fixing a price band of ₹549 to ₹577 per equity share of face value ₹2.

see more..

Festive demand, GST cut drove record vehicle dispatches in Oct: SIAM

15 Nov 2025 | 12:52 AM

New Delhi, Nov 14 (UNI) India’s automobile sector posted its strongest monthly performance to date in October 2025, with passenger vehicles, two-wheelers, and three-wheelers recording their highest-ever dispatches to dealerships, said SIAM data released today.

see more..

Ajman NuVentures Free Zone achieves strong first-year growth; nearly half new firms Indian

14 Nov 2025 | 11:49 PM

Mumbai, Nov 14 (UNI) The Ajman NuVentures Centre Free Zone (ANCFZ) of the United Arab Emirates has recorded a strong debut year, successfully registering more than 6,500 companies since its establishment in October 2024, marking a significant milestone in its efforts to attract global investors.

see more..